US pricing erosion may resume
While pricing has stabilized recently, any reversal could pressure US margins and revenue growth.
AUROPHARMA / bear-case history
Track the concerns that keep returning.
Aurobindo Pharma · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Revlimid launch volume uncertainty
As a late entrant, Aurobindo's Revlimid volume share is expected to be lower than early entrants, limiting upside.
PLI Pen-G ramp-up delays
Management acknowledged that full ramp-up of Pen-G capacity may take time, with clarity only expected by February 2024.
Biosimilar revenue visibility low
Management declined to provide revenue projections for biosimilars, citing evolving market dynamics, indicating high uncertainty.
Pen-G ramp-up delays
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
Injectables remediation and FDA compliance
Eugia Unit III remediation cost $9M in Q1; Bhiwadi plant received OAI. Further regulatory actions could disrupt injectable sales.
US price erosion and competition
Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
Biosimilar approval delays
Biosimilar filings with EMA and FDA are subject to regulatory uncertainties; delays could push revenue contribution beyond FY26.
Sustained API pricing pressure
API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.
FTC approval delay for Lannett acquisition
The Lannett acquisition is subject to FTC approval, which could take 8-12 months or longer, delaying synergies.
Generic Revlimid revenue tailwind fading
Generic Revlimid sales have largely been exhausted, with minimal future contribution expected, impacting U.S. revenue.
U.S. tariff and domestic manufacturing push uncertainty
Potential U.S. tariffs and push for domestic manufacturing could increase costs and alter competitive dynamics.
Price erosion in US generics
While current price erosion is neutral, increased competition could pressure margins in oral solids and injectables.
Execution risk in new plant ramp-ups
Pen-G, China, and biosimilar plants face commissioning delays; revenue contribution may shift to FY26.
Depreciation and impairment charges
Higher depreciation due to impairment provisions may persist, impacting reported profitability.
Dependence on gRevlimid for margin target
Analyst questioned if 20% margin guidance includes gRevlimid; management confirmed, but any volume/pricing shortfall could miss target.
Sustained high R&D spend
R&D costs jumped ~INR 70 crore in Q2 due to phase III biosimilar trials; management expects elevated spend for at least four more quarters.
Freight cost volatility from Red Sea disruptions
Higher freight costs (~INR 30 crore impact) due to Red Sea issues; management expects normalization but uncertainty remains.
Unit 3 injectable supply chain recovery timeline
Injectable sales declined 11% YoY due to voluntary production slowdown at Unit 3; full recovery expected only by Q4, with FDA reinspection likely in FY26 Q3.
Biosimilar omalizumab recruitment delays
Phase III recruitment for omalizumab is 3-4 months behind schedule, potentially pushing back filing timelines.
UGF3 reinspection delay
FDA reinspection for UGF3 facility is pending; timeline is uncertain (up to 8 months from September 2025), delaying injectable product launches.
Pen-G MIP policy uncertainty
Minimum import price (MIP) representation to government is pending; if delayed or denied, Pen-G ramp-up and profitability may be impacted.
Biosimilar competitive intensity
New FDA draft guidance may lower entry barriers, increasing competition; Aurobindo may be third or later entrant in key products like denosumab.
High CapEx intensity
H1 CapEx at INR 1,500 crore; ongoing investments in biosimilars, biologics CMO, and Pen-G may pressure cash flows despite unutilized capacities.
Eugia Unit III FDA observations and production halt
FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.
Potential market share loss in injectable products
Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.
Penicillin G plant pricing risk
Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.
Biosimilar commercialization delays
Pneumococcal vaccine missed national tender timeline; management indicated no near-term market entry, highlighting execution risk in biosimilar launches.
Generic Revlimid patent expiry impact
Patent expiry in January 2026 could lead to pricing erosion and market share loss; management acknowledged uncertainty but plans to continue supply post-expiry.
Eugia injectables capacity ramp-up delays
Capacity utilization at Eugia remains at 50% due to supply challenges; any further delays in returning to normal run-rate could impact US injectable revenue.
Biosimilar clinical trial delays
Omalizumab and ophthalmic product trials are delayed; ophthalmic recruitment only 50% and expected to complete in H2 2026, pushing back potential launches.
US tariff risk on pharmaceuticals
Potential US tariffs on pharmaceutical imports could impact margins; management believes existing US manufacturing footprint provides mitigation.
Eugia warning letter resolution uncertainty
Despite procedural observations, the USFDA decision on the warning letter is pending; management is cautiously optimistic but cannot predict outcome.
6-APA predatory pricing impact
6-APA prices have been below cost of manufacture internationally, causing losses; correction expected by April but timing uncertain.
Lannett acquisition regulatory delays
FTC approval process is ongoing; any delay or unexpected conditions could impact the timeline and synergies.
Ramp-up costs from multiple greenfield projects
EBITDA burn from ramping up facilities like Pen G, Dayton, Raleigh, and biosimilars may pressure near-term margins.
Eugia 3 OAI status may delay ANDA approvals
Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.
Biosimilar monetization timeline pushed to 2027-2028
Management expects meaningful biosimilar revenue only by 2027-2028, later than some investor expectations.
Pen-G ramp-up complexity may delay benefits
Pen-G fermentation is complex; yield optimization will only be addressed by September, posing execution risk.
Ryzneuta launch in US faces competitive pressure
Management is conservative on Ryzneuta (pegfilgrastim biosimilar) launch, citing multiple competitors and uncertain pricing.
Pen-G plant fire disruption
A fire incident at the Pen-G facility in Kakinada has halted production; resumption depends on regulatory approvals, impacting FY26 revenue and margin assumptions.
Potential US tariffs on pharmaceutical imports
Tariff announcements expected in July 2025 could impact US business; management declined to provide specific guidance until clarity emerges.
Muted injectable growth in FY26 due to Eugia-3 remediation
Eugia-3 facility remains under FDA remediation; injectable growth is expected to be flat in FY26, with recovery only in FY27.
Revlimid revenue decline in FY26
Revenue from Revlimid will be significantly lower in FY26 as the product faces increased competition and limited remaining supply.